Overview

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Status:
Recruiting

Trial end date:
2020-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Medical University

Treatments:

Apatinib
Capecitabine
Oxaliplatin